Telmisartan+HCTZ, Hypertension

This study has been completed.

First Received: April 10, 2008 Last Updated: January 28, 2009 History of Changes

Sponsored by:	Boehringer Ingelheim Pharmaceuticals
Information provided by:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00659607

Purpose

This PMS study aims to review the followings by investigating the actual practice of MicardisPlus Tablet on the market:

Condition
Hypertension

MedlinePlus related topics: High Blood Pressure

Study Type:	Observational
Official Title:	PMS Study of MicardisPlus Tablet

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Enrollment:	6764
Study Start Date:	September 2003
Primary Completion Date:	July 2008 (Final data collection date for primary outcome measure)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

patients diagnosed with essential hypertension

Exclusion Criteria:

n/a

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00659607

Sponsors and Collaborators

Boehringer Ingelheim Pharmaceuticals

Investigators

Study Chair:

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals

More Information

No publications provided

Responsible Party:	Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair )
Study ID Numbers:	502.475
Study First Received:	April 10, 2008
Last Updated:	January 28, 2009
ClinicalTrials.gov Identifier:	NCT00659607 History of Changes
Health Authority:	Korea, Republic of: Korea Food and Drug Administration

Study placed in the following topic categories:

Vascular Diseases
Telmisartan
Hypertension

Additional relevant MeSH terms:

Vascular Diseases
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on May 07, 2009